Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma

NCT01656980 is registered in ClinicalTrials.gov with Shandong Lanjin Pharmaceuticals Co.,Ltd as lead sponsor.

NCT NCT01656980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01656980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma
Lead sponsor
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase
Phase 3
Overall status
Unknown status
Start date
August 31, 2012
Completion date
December 31, 2014
Enrollment
236 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma